Peptides for belly fat and liver health: what TikTok gets wrong

What did @mindandfuel actually say?

The creator held up an unnamed peptide and claimed it "absolutely torches belly fat at a disproportionate rate" while simultaneously producing "the best improvements we've ever seen in liver health." A guest was then brought in to confirm that the FDA is set to "consider legalizing seven peptides" in July, and the conversation wrapped up with a straight-faced accusation that Big Pharma is suppressing these compounds because they can't be patented.

To be clear: no specific peptide was named. No patient data was cited. No study was referenced. The framing was built almost entirely on vague superlatives, a guest nodding along, and a conspiracy hook. That's not a health claim. That's a sales pitch structured to feel like a medical briefing.

Does the science back this up?

Some peptides do have real, peer-reviewed evidence for metabolic effects, but the sweeping claims made here outrun the data by a wide margin. The most credible candidate matching this description is likely a GLP-1 receptor agonist-adjacent compound or possibly AOD-9604, though neither perfectly fits the framing used.

AOD-9604, a modified fragment of human growth hormone, has shown some fat-oxidation activity in animal models, but human trial results have been underwhelming. A 2004 phase IIb trial published in the International Journal of Obesity (Ng et al.) showed modest dose-dependent weight loss, but the compound failed to achieve FDA approval for obesity. On liver health, the evidence base for peptides is mostly preclinical. BPC-157 has shown hepatoprotective effects in rodent studies (Sikiric et al., 2016, Current Pharmaceutical Design), but translating that to "best improvements we've ever seen" in human patients is a leap the data doesn't support. The phrase "disproportionate rate" of belly fat loss implies visceral-specific fat targeting, which is a mechanistic claim that would require imaging-confirmed RCT data to stand up.

What did they get wrong (or right)?

The FDA regulatory framing deserves its own section because it's the most verifiable claim in the video, and it's badly distorted. The FDA did issue guidance in 2023 and 2024 around compounded peptides, but "considering legalizing seven peptides" is not accurate language for what happened. The FDA placed several peptides, including BPC-157 and TB-500, on a list of substances that cannot be compounded under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. That is the opposite of legalization. It restricts access through compounding pharmacies.

The guest's claim that this is "110%" confirmed Big Pharma suppression because peptides "can't be patented" is a conspiracy trope that ignores how drug development actually works. Peptides absolutely can be patented through method-of-use patents, formulation patents, and delivery mechanism patents. Semaglutide (Ozempic) is a peptide. It is very much patented. The suppression narrative collapses under basic scrutiny.

What they got partially right: some peptides do have early evidence for metabolic and hepatic effects, and the regulatory environment around compounded peptides is genuinely in flux. Those are real topics worth discussing honestly.

What should you actually know?

The peptide space is legitimately interesting and legitimately complicated. There are compounds with serious early-stage evidence for metabolic support, tissue repair, and other applications. The problem is that "serious early-stage evidence" and "absolutely torches belly fat" are not the same sentence.

If you're considering peptide therapy, you need to know a few things. First, most bioactive peptides discussed in biohacking circles are not FDA-approved for the uses being promoted. Second, the compounding pharmacy landscape shifted significantly with FDA guidance issued in 2023 and 2024, meaning access through regulated channels is narrowing, not expanding. Third, "trillion dollar drug" language in a TikTok video is a financial hype signal, not a clinical one. Fourth, liver health is not a casual marketing claim. Non-alcoholic fatty liver disease is a serious condition managed by hepatologists, not supplement stacks. Any claim of meaningful liver improvement should come with liver enzyme panels, imaging data, and peer-reviewed methodology, not anecdote.

The framing in this video, that a mystery peptide does everything and that powerful forces want to keep it from you, is a rhetorical structure designed to bypass critical thinking. It works. That's why it has 7,100 views. It doesn't mean it's accurate.